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Abstract
The usefulness of parameters measured using the pulmonary artery
catheter has been challenged because no benefit in patient
outcome has been observed in clinical trials. However, techno-
logical advances have been made, including continuous
measurement of cardiac output (CO), mixed venous saturation
(SvO2), and right ventricle end-diastolic volume (CEDV) have been
made. Pulmonary artery occlusion pressure (PAOP), CEDV and
right atrial pressure (RAP) are not good predictors of fluid load
responsiveness except when very low. Despite this methodological
limitation, variation of these parameters during fluid loading remains
a good indicator of fluid challenge tolerance. Accuracy of
continuous thermodilution and SvO2 measurement has been
demonstrated in vitro and at bedside. A decrease in SvO2 is a
global index of an inadequate oxygen delivery (DO2)/oxygen
requirement relationship. In this setting, a therapeutic decision to
improve determinants of SvO2 should be considered with the help
of all other PAC parameters. Technological improvement trans-
forms PAC in a real time integrated physiological device and allows
one to observe the impact of therapeutic intervention. What we
need now is a clinical trial with a PAC-guided treatment algorithm
taking into account the above integrated PAC parameters. 
Introduction
More than 35 years ago, Harold James Swan (who died on 7
February 2005, just after writing his last contribution,
published in Anesthesiology [1]), along with William Ganz
and collaborators, reported an article entitled ‘Catheterization
of the heart in man with the use of a flow-directed balloon-
tipped catheter’ [2]. The first catheter was intended
exclusively to measure right heart and pulmonary artery (either
occluded or not) pressures. Following an idea by Ganz, a
thermistor was incorporated into the catheter and a reliable
method to measure cardiac output (CO) by thermodilution
was developed. The first report on the pulmonary artery
catheter (PAC) was centred on myocardial ischaemia, but
application of the PAC was quickly extended to other
pathologies and settings including cardiac failure, septic
shock, acute respiratory distress syndrome (ARDS), cardiac
surgery and high-risk surgery.
The general design of the PAC did not change for more than
three decades; however, technological progress has recently
been achieved. The incorporation of a rapid response
thermistor permitted continuous measurements of CO, right
ventricular ejection fraction (RVEF) and right ventricular end-
diastolic volume (RVEDV). Also, the addition of an fibreoptic
canal permitted continuous spectrophotometric measurement
of mixed venous oxygen saturation (SvO2).
Are the classic and new parameters reliable at the bedside?
When using PAC, how may we better understand the various
pathologies and how may we devise a better therapeutic
strategy in critical care and anaesthesiology? These are some
of the questions we address in the present review.
Parameters from the pulmonary artery catheter
Pressure in the pulmonary circulation
Pulmonary artery occlusion pressure
The pulmonary artery occlusion pressure (PAOP) is obtained
following inflation of the balloon at the tip of the PAC. In
theory, after inflation of the balloon there is a continuous
column of blood from the pulmonary artery to the left ventricle
during diastole. The end of the diastole can be identified by
the ‘a’ wave of the PAOP curve, which coincides with the ‘p’
wave on the electrocardiogram. Consequently, PAOP is
considered an approximation of the left ventricular end-
diastolic pressure (LVEDP) [3]. For a given left ventricular
compliance, LEVDP is proportional to the left ventricular end-
diastolic volume (LVEDV). As described by the Frank–
Starling relationship, the force of ventricular contraction is
proportional to the length of the myocardial fibres, as
determined by LVEDV. Therefore, PAOP can be considered
an indicator of preload.
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Knowledge of preload is fundamental to clinical practice in
intensive care or during surgery. For example, when other
haemodynamic parameters (e.g. SvO2, serum lactate concen-
tration, or renal function) suggest to the clinician that tissue
perfusion must be improved via increased oxygen delivery
(DO2), preload determination allows the clinician to choose
between fluid loading and inotropic drugs. In other
pathologies, such as left ventricular failure or ARDS, preload
must be controlled to avoid worsening of pulmonary oedema.
However, the assumption that pulmonary artery occlusion
always induces a continuous blood column may not be valid
in some cases (Figure 1). First, when the catheter tip is in
West zone 1 or 2, the increase in alveolar pressure interrupts
the blood column. Consequently, PAOP is higher than end-
diastolic pulmonary pressure and pulmonary venous
pressure. To address this problem, the catheter tip must be in
West zone 3. If this is the case, then the following
relationship will be present during the respiratory cycle in
mechanically ventilated patients [4]: end-diastolic pulmonary
pressure > PAOP, and ∆PAOP/∆PAP > 1.5 (where PAP is
the pulmonary artery pressure). Second, in mitral valve
disease PAOP reflects the increase in left atrial pressure and
not the LVEDP. In mitral stenosis the PAOP trace has a large
‘a’ wave and in mitral regurgitation a large ‘v’ wave. Finally, all
changes in ventricular compliance (the LVEDP/LVEDV
relationship) induce overestimation of preload by PAOP.
Modification to left ventricular compliance may result from
numerous pathologies, including myocardial ischaemia and
failure, myocardial hypertrophy or dilatation, septic chock,
aortic disease and pericardial disease.
Despite these practical limitations, PAOP provides some
useful information. When dynamic preload dependency
indicators (see below in this paragraph) are unreliable (i.e. in
the presence of arrhythmia or spontaneous ventilation, among
other conditions), it is always possible to establish a Frank–
Starling relationship between PAOP and stroke volume
variation (or CO) following successive fluid challenges. The
stroke volume does not increase any further after additional
fluid challenge when the flat part of the Frank–Starling curve
is reached, indicating preload independency. In pulmonary
arterial hypertension a difference (>7–8 mmHg) between
diastolic PAP and PAOP indicates an increase in pulmonary
artery (or capillary) resistance, and primary pulmonary hyper-
tension is diagnosed. In contrast, pulmonary arterial
hypertension without any gradient is secondary to increased
pulmonary venous resistance, and causes of altered left
ventricular compliance (e.g. myocardial ischaemia or left
ventricular failure) or mitral disease must be explored.
Figure 1
Schematic representation of PAOP. The grey area represents the area without flow. Examples are given of pathologies in which PAOP is not
equivalent to left ventricular preload. LA, left auricle; LAP, left atrial pressure; LV, left ventricle; LVEDP, left ventricular end-diastolic pressure;
LVEDV, left ventricular end-diastolic volume; PAOP, pulmonary artery occlusion pressure; RA, right auricle; RV, right ventricle.Page 3 of 10
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Preload dependency
Right atrial pressure and central venous pressure have largely
been used as static preload indicators. During the past
decade, however, several dynamic indicators for preload
dependency such as pulse pressure variation or ∆down have
been studied. In most of these studies, these parameters were
compared with the classic static parameters such as PAOP or
central venous pressure [5]. Compared with dynamic
indicators, static parameters have poor ability to predict
responsiveness to fluid challenge, except when they are very
low (less than 5 mmHg) [6,7]. Static parameters cannot
therefore be recommended as indicators of preload depen-
dency, and PAOP cannot be used as a first-line tool to make
fluid loading decisions if dynamic parameters are available.
Dynamic parameters also have limitations in settings such as
cardiac arrhythmia, spontaneous ventilation, high-dose vaso-
pressors and right ventricular failure. Dynamic indices are
unable to predict volume of fluid challenge and tolerance to a
subsequent fluid challenge when the patient’s volume status
is on the upper part of the slope of the Frank–Starling
relationship. In this setting the PAOP remains a good
indicator of fluid challenge tolerance; a large increase in
PAOP (5–10 mmHg) after one fluid challenge indicates that
further fluid loading should be considered with caution. Fluid
responsiveness is a better basis for decisions regarding fluid
loading; however, it is not equivalent to fluid loading
tolerance. Therefore, static and dynamic preload parameters
provide complementary information.
Pulmonary capillary pressure
As described above, increased gradient between PAOP and
diastolic PAP indicates increased pulmonary resistance or
increased pulmonary blood flow, or both. In these settings,
pulmonary capillary pressure (Pcp) may exceed PAOP [8].
Therefore, an increased gradient between diastolic PAP and
PAOP is considered a valuable indicator of increased Pcp.
The resistance between pulmonary artery and left atrium can
be simply modelled as one artery resistance and one venous
resistance in series, with a capacitance located in the
capillary bed [9,10]. Because of this series resistance with a
capillary capacitance, the Pcp can be measured from the
pressure decay profile after occlusion of the balloon
(Figure 2). After occlusion of the pulmonary artery, the
downstream blood is discharged into the capillary across
arterial resistance and then into the pulmonary veins across
venous resistance [8]. The initial rapid drop in pressure
reflects the Pcp as the downstream blood is trapped in the
capillary bed and equilibrates with the Pcp. The following
slower drop in pressure is determined by the discharge of
blood across the pulmonary venous resistance and tends
toward the PAOP (Figure 2).
The more sophisticated approach to determining the Pcp
includes the average smoothing of the pressure signal and
mathematical curve fitting of the signal. With an approach
that is more realistic at the bedside, the Pcp can be
measured using a graphical method; the Pcp is estimated as
the point at which the pressure curve deviates from the slope
of the first rapid decay (Figure 2).
Because Pcp is the main determinant of efflux between
capillary lumen and alveolar space, whether the integrity of
alveolar–capillary barrier is impaired or not, its measurement
may be of interest in pathologies such as ARDS to guide fluid
loading [8]. A Pcp threshold value must be determined above
which pulmonary oedema develops, and pulmonary
compliance and gas exchange are impaired. Fluid loading
should be then limited to this threshold value as much as
possible, taking into consideration the perfusion of other
organs. Further studies are evidently necessary to explore the
utility of such a strategy and to develop new tools for
automatic measurement of Pcp.
Continuous measurement of end-diastolic volume and
ejection fraction
In the 1980s, technological improvements led to the
introduction of the ‘volumetric’ pulmonary catheter. These
catheters differ from the previous version in three different
ways [11]. They have two intracardiac electrodes that allow
continuous measurement of the patient’s electrocardiogram
and of the R-R interval (or a connection with cardiac
monitoring in more recent devices); they have a rapid
response thermistor (response time between 50 and 70 ms);
and they have a special injection port that allows more
complete distribution throughout the right ventricle.
The ‘volumetric’ PAC thermodilution curve is processed and
the logarithmic decay portion of the curve is calculated on a
beat-to-beat analysis, as determined by the intracardiac
electrodes. By calculating the residual temperature change
between beats, the computer determines the RVEF. The
RVEF is then used to calculate the RVEDV, as described in
the following equation:
RVEDV = CO/(heart rate [beats/min] × RVEF)
RVEDV should represent a left ventricle preload indicator, but
some major problems were identified in the earliest studies.
RVEDV was compared with PAOP, which is acknowledged
to be a poor indicator of preload dependency. There is
mathematical coupling between CO and RVEDV, because
the RVEDV index is calculated from stroke volume. This
mathematical coupling has been proposed to account for the
significant correlation between these two parameters. To
overcome this methodological problem, several authors
measured CO independently using indirect calorimetry, two
different thermodilution technologies, or transoesophageal
echocardiography [12,13]. In those studies, RVEDV
remained correlated with CO, and RVEF measured using a
‘volumetric’ PAC was equivalent to RVEF measured using
another method.
Available online http://ccforum.com/content/10/S3/S3That the new, volumetric PAC can measure both RVEF and
RVEDV is an important feature. Continuous measurement of
RVEF and of RVEDV (CEDV) should be useful in guiding
haemodynamic treatment. RVEF reflects the right ventricular
contractility and afterload, whereas RVEDV provides
information on right ventricular preload. Initial studies found a
good correlation between RVED and CO, but in most of
them the RVEDV was no different before and after fluid
loading, challenging the ability of RVEDV to predict fluid
responsiveness [14-17]. However, in two studies indexed
RVEDV was significantly lower before than after fluid
challenge [18,19]. Above a value of 138 ml/m2 patients did
not respond to further fluid loading with an increase in CO,
and under 90 ml/m2 a high percentage of patients were
responders to fluid loading. However, between these two
values RVEDV index was unable to predict fluid
responsiveness. This lack of ability to predict preload
dependency was recently confirmed during cardiac surgery
in which CEDV was used [20]. The concept of an optimal
value of RVEDV was probably an oversimplification of a
complex relationship between preload, contractility and
afterload. Because of contractility and afterload, RVEF
should probably be taken into consideration when
interpreting RVEDV. However, if a single value of RVEDV is
unable to predict fluid responsiveness, then trends over time
should be of interest if they are combined with other
parameters from the PAC, particularly continuous CO
(CCO) and continuous measurement of SvO2. Right
ventricular failure could be another field of interest for CEDV,
particularly in guiding treatment.
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Figure 2
A schematic representation of the electric circuit analogue of the pulmonary circulation. (a) Pulmonary artery pressure decay after occlusion of the
balloon during a respiratory hold in the presence of mechanical ventilation. (b) An additional trace using 20 data point moving average smoothing
of the original trace (collected at 100 Hz) is superimposed on the curves. This further facilitates the visual estimation of the capillary pressure by
defining more precisely the point of divergence of the occluded and nonoccluded curves. In addition, an exponential curve has been fitted onto the
curve 0.3-2 s after occlusion. This fitted curve has been extrapolated to the time of occlusion to provide the capillary pressure. Pcap, pulmonary
capillary pressure. Reproduced with permission from Takala [8].Cardiac output determination
Thermodilution: the bolus method
Measurement of CO using a PAC is based on the injection of
tracer into the right atrium and analysis of the change in its
concentration in the pulmonary artery. If it is assumed that the
mass (M) of tracer is constant, then it has been shown that M
is equal to the product of the blood flow (Q) and its
concentration over time (C), as expressed in the Stewart–
Hamilton equation.
M = Q × ∫C(t)dt
Currently, the tracer usually used is an injection of cold
solution in the right atrium. The temperature variation is
monitored in the pulmonary artery. The above equation can
be expressed as follows:
Vi (Tb – Ti) (ρiCi/ρbCb) = Q × ∫Tdt
Q = Vi (Tb – Ti) × (ρiCi/ρbCb)/∫Tdt
Where Vi is the volume of injectate, Ti is the temperature of
injectate, Tb is the blood temperature, T is the variation in
temperature over time, ρi and ρb are the specific gravities of
injectate and blood, and Ci and Cb and the specific heats of
injectate and blood.
The final Stewart–Hamilton equation includes a correction
factor that depends on the type of catheter used [21]:
Q = Vi (Tb – Ti)/S × (ρiCi/ρbCb) × k
Where S is the area under the thermodilution curve and k is
the catheter constant.
Despite these correction factors, several methodological
limitations persist [3,22]. First, heat transfer to right atrium
blood, wall and surrounding tissue lead to overestimation of
CO. Intracardiac shunts, baseline temperature variation in
pulmonary artery blood, abnormal haematocrit and cardiac
arrhythmia are other sources of errors. Second, conditions
surrounding the injectate infusion may represent a further
source of error. A 10 ml injectate at room temperature seems
adequate in most circumstances (2.6–4.2 l/min per m2), but
cold injectate is recommended in low flow and hyperdynamic
states. Variations in volume and speed of the cold tracer
infusion can induce differences between measurements.
Mechanical ventilation induces complex variations in CO,
which depend on the clinical situation. For all of these
reasons, variations between two single measurements of up
to 25% can occur, and it is therefore recommended that a
minimum of three bolus measurements throughout the
respiratory cycle be averaged. The variation between two
series of three measurements is reduced to 15%. A third
methodological limitation is that rapid change in temperature
induced by rapid fluid administration (>1 l/hour), use of an
upper body warming blanket and extracorporeal oxygenation
decrease the accuracy of CO measurement. Finally, in
tricuspid regurgitation the transit time of the tracer is
increased and the temperature is modified by regurgitation of
blood into the right atrium. Therefore, tricuspid regurgitation
can induce overestimation or underestimation of CO.
Continuous cardiac output
In contrast to intermittent thermodilution, the tracer used for
CCO is not cold but warm. A 10 cm thermal filament is
inserted into the catheter at the level of the right ventricle. The
surface temperature of the filament is always below 44°C.
Low levels of heat energy are transferred to the blood
according a pseudo-random binary sequence. A cross-
correlation based on the input sequence and the downstream
signal measured by the thermistor is performed. The heat
signal is processed over time and the classical thermodilution
curve is rebuilt. CO is determined using a modified
Stewart–Hamilton equation. The CO value is an average over
a 3 min period (minimum) [22] and not a beat-to-beat
measurement. It is an ‘almost’ continuous CO measurement.
In vitro studies found good accuracy but with a systematic
trend toward overestimation [23]. The degree of over-
estimation is nevertheless lower with CCO than with the
bolus method [23]. CCO has been evaluated in humans in
comparison with reference methods such as the Fick method,
dye dilution (indocyanin green) and electromagnetic
measurement of aortic blood flow (often considered the ‘gold
standard’ in the cardiac laboratory) [24-26]. In all studies the
bias was acceptable (–0.48 to +0.35 l/min, with precision of
0.56–0.74 l/min) [24-26]. Accuracy of the bolus method is
lower with very high and very low CO. The classical
limitations of thermodilution also apply to CCO monitoring,
but because the CCO value represents an average of
measurements made over a period of time, it might be
expected that increasing the integration period of the signal
could decrease the influence of the usual factors that limit the
thermodilution technique, such as tricuspid regurgitation,
cardiac arrhythmia and baseline variation of pulmonary artery
blood, among others. When compared with the bolus
method, CCO determination has negligible bias but exhibits
better reproducibility, probably because CCO monitoring
avoids interindividual variations in volume and speed of
infusion of the tracer bolus [27].
Mixed venous oxygen saturation
In several studies a drop in SvO2 has been associated with a
poorer prognosis after cardiac surgery [28], in severe
cardiopulmonary disease [29], and in cardiogenic and septic
shock [30,31]. Therefore, SvO2 monitoring should be of
interest in critically ill patients. SvO2 is considered an index of
global oxygenation, reflecting the balance between DO2 and
oxygen consumption (VO2). The main determinants of SvO2
are VO2, haemoglobin, arterial oxygen saturation (SaO2) and
CO. At constant VO2 and with haemoglobin and CO within
Available online http://ccforum.com/content/10/S3/S3
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and CO. Because the mathematical relationships between
SvO2 and its determinants are linear (VO2 and SaO2) or
curvilinear (haemoglobin and CO), the weight of these
determinants is not the same; the influence of VO2 and SaO2
is independent of their absolute values, but a small decrease
in CO in a hyperdynamic state does not induce any change in
SvO2. Impaired microcirculation, as occurs in severe sepsis or
septic shock, induces a deficit in oxygen extraction so that
the SvO2 will not necessary decrease, even in the presence of
an inadequate VO2/DO2 relationship. In this situation a normal
SvO2 is not equivalent to adequate organ perfusion. Finally,
the SvO2 is a global index of oxygenation, and does not
provide information on regional perfusion.
For all of the reasons given above, SvO2 must be interpreted
with caution. It is not an index of inadequate CO, and each of
the four determinants must be considered. However, whether
SvO2 does or does not correlate with CO is not of major
importance. In the majority of cases a decrease in SvO2
represents an alert that the global VO2/DO2 relationship is
inadequate, regardless of the source of this decrease. For
example, even if the drop in SvO2 is secondary to an increase
in VO2 (and not to a decrease in CO or DO2) during weaning
from mechanical ventilation, this variation in SvO2 must be
taken into consideration because it reflects the fact that the
cardiorespiratory status of the patient does not fit the new
situation. In this example one should consider whether there
is a need for transfusion, whether left ventricular failure is
present and the respiratory load; postponement of weaning
may be necessary [32]. Hence, even when CO is not directly
involved in a SvO2 variation, reconsideration of therapeutic
approach can ensue.
Continuous measurement of mixed venous oxygen
saturation
In several studies, an unexpected drop in SvO2 has been
observed following cardiac surgery, emphasizing the
potential value of continuous SvO2 monitoring [33,34].
Measurement of SvO2 has been available since fibreoptics
were incorporated into the PAC. Spectrophotometry is the
reference technique for measuring oxygen saturation. The
absorption spectrum of red blood cells depends on the
relative concentrations of oxyhaemoglobin and haemo-
globin. Using the continuous method, the emitted light
illuminates the blood within the vessel lumen, and is
backscattered and refracted by the different blood cells and
the vessel wall. The reflected light is retransmitted to a
photodetector by one or two bundles of fibreoptics.
Depending of the device, two or three wavelengths
between the red and infrared domains are used. Oxygen
saturation is assumed to be a function of the ratio of
reflected light at the various selected wavelengths.
The accuracy of continuous measurement has been tested in
vitro and in vivo [35-38]. In both the correlation is good and
bias – in those studies that reported it – is small. Ideally,
continuous measurement of SvO2 should be done over
24 hours; this avoids significant drift and the need for
recalibration. However, several factors have been found to
influence the accuracy of the method, namely blood flow
velocity, distance between the catheter and the vessel wall,
red blood cell shape and refractive index of the plasma [22].
The use of three wavelengths, which is theoretically better at
avoiding such disturbances, was not found to be more
accurate than using two wavelengths in a clinical study [39].
Taking into account the ratio of benefit to risk with pulmonary
artery catheterization, a central venous catheter with continuous
monitoring of oxygen saturation (central venous oxygen
saturation [ScvO2]) has been developed. Several studies have
compared the accuracy of the two methods [40,41]. In
critically ill patients there is a systematic positive shift of
between 5 and 8 mmHg in ScvO2 compared with SvO2 [40].
This shift may be explained by a relative increase in cardiac
and cerebral blood flow in circulatory failure and a
redistribution of blood flow in sepsis associated with a
proportionally reduced blood flow in hepatic, splenic,
mesenteric and renal territories. In most studies there is a
wide range of 95% limits of agreement (when available) in
intensive care as well as in anaesthesiology, indicating
variability between the two methods [40,41]. Therefore,
individual values of SvO2 and ScvO2 are not equivalent.
However, in the same studies [40,41] the bias was low
(<2–3%), indicating that the trends of SvO2 and ScvO2 are
similar (Figure 3). Clinical decisions are rarely based on a
single measurement of a single parameter. Trends in these
parameters and their variations following therapeutic
decisions are often more interesting.
If we are to use SvO2 as a parameter for haemodynamic
monitoring, then we must define a threshold value. A few
years ago, Rivers and coworkers [42] used continuous
monitoring of ScvO2 in an early goal-directed therapy
algorithm in severe sepsis and septic shock patients. The
threshold value of ScvO2 was 70%. That approach was
effective; the mortality rate in the early goal-directed therapy
group was decreased by 16.7% in comparison with the
control group. If we consider the shift of 7 mmHg between
SvO2 and ScvO2 in critically ill patients [40], a SvO2 threshold
of around 65% should be used in further studies.
Pulmonary artery catheter as an integrated
physiological tool in clinical practice
To this day data on PAC use does not indicate benefit for
unstable patients in the intensive care unit [43-46]. Some
results are more promising in high-risk surgical patients but
remain contradictory [45,47,48]. In a recent report a large
database of patients with severe trauma was developed;
patients with severe trauma, severe shock and older patients
had better survival when treated with the help of a PAC.
Therefore, data from PAC use are rather confusing and
Critical Care    Vol 10 Suppl 3 Robin et al.
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lack of controlled trials with treatment algorithms including all
PAC parameters than the ineffectiveness of PAC guidance.
Some of them compared PAOP with central venous pressure
in predicting response to fluid loading. However, neither
PAOP nor central venous pressure is a good indicator of
preload dependency [5]. Other trials used CO measurement
by PAC to achieve ‘supranormal’ oxygen transport in critically
ill patients [49,50]. In this latter setting, it is not the accuracy
of CO measurement by PAC that is challenged but the
pathophysiological hypothesis that there is any benefit from a
‘supranormal’ oxygen transport [49-52].
It does not make sense to use a PAC, with the attendant
potential adverse events of right cardiac catheterization,
without using all of its capabilities. CO is probably the main
parameter used in most studies, but CO is a regulated
variable and it is necessarily arbitrary to predetermine a CO
threshold value. There is no good or bad CO value, but there
is CO that permits or does not permit an adequate DO2. As a
global index of adequacy between VO2 and DO2, SvO2 is the
target of choice for therapeutic decisions. SvO2 should be
kept above a threshold value and all other PAC parameters
should be used to choose how to maintain SvO2 above this
threshold value. As described above, a threshold value
between 65 and 70% should be used in future studies. There
are few studies using SvO2 as one of the main therapeutic
targets. In a study conducted in cardiac surgery patients [28],
the first objective in the goal-oriented haemodynamic group
was to keep the SvO2 above 70% and lactate serum
concentration below 2 mmol/l. This SvO2 goal was achieved
by giving more fluid loading, more inotropic drugs and less
vassopressor medication. The result was a decrease in
morbidity and in-hospital stay. A more impressive example
was reported by Rivers and coworkers [42]. The very early
timing of the protocol and the quick transfer to intensive care
certainly played some role in the success of this study.
Clearly, ScvO2 is the therapeutic target that explained most of
the difference between the control and the optimized group,
prompting faster fluid loading, more red blood cell
transfusions and – in a few patients – administration of an
inotropic drug (dobutamine). Therefore, in future studies
using a PAC, SvO2 should be at the centre of the
haemodynamic algorithm. Preload indicators (PAOP, right
atrial pressure, CEDV), CO and other parameters such as
hemoglobin concentration and arterial oxyhaemoglobin
fraction must be used to choose the optimal way to achieve
the desired objective of an SvO2 above 70%. Of course, such
a strategy should not be applied in too dogmatic a way. The
clinical context should always be taken into consideration. For
example, a patient with a severe systolic dysfunction following
extensive myocardial infarction would certainly have an SvO2
below 70%. However, if the function of the other organs is
not compromised, then optimization of CO by inotropic drugs
might impair the myocardial dysfunction further and have an
affect opposite to that expected.
Conclusion
Since the beginning of the 1970s, PAC has been the
reference method for haemodynamic monitoring in critically ill
patients. Despite the arrival of new devices (invasive or not),
thermodilution is the reference method for measuring CO at
bedside. The possibility to measure continuously some
parameters such as CO, SvO2 and CEDV provides further
insight when monitoring. With former PAC technology (as
opposed to the continuous PAC), the haemodynamic status
of patients was assessed every 4–6 hours in the best case.
Many haemodynamic events were missed by intermittent
measurements. Several studies, most of them conducted in
patients who had undergone cardiac surgery, revealed
unpredictable variations in CO or SvO2 without necessarily
any change in other haemodynamic parameters [33,34,53].
More importantly, continuous monitoring allows physicians to
observe the impact of therapeutic interventions, such as fluid
loading, inotropic agents, vasopressor and blood transfusion.
Continuous monitoring provides a useful guide to therapeutic
intervention, and the initial diagnosis may be challenged in
case of therapeutic failure.
Numerous devices have been introduced during the past
decade for haemodynamic monitoring, some of which are
less invasive than PAC placement. Echocardiography is an
impressive diagnostic tool, but it can not be repeated
indefinitely over time and is operator dependent. Pulse
contour methodology has the same limitations as thermo-
dilution (or dye dilution) with respect to calibration, and it is
largely influenced by variation in arterial compliance.
Oesophageal Doppler must be replaced frequently if patients
are not deeply sedated. All of these devices are less invasive
Available online http://ccforum.com/content/10/S3/S3
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Figure 3
Continuous measurement of SvO2 and ScvO2. Shown is the time course
of continuous measurement of SvO2 and ScvO2 in a patient with acute
respiratory distress syndrome who developed tension pneumothorax,
which was treated by insertion of a chest tube. SvO2, mixed venous
oxygen saturation; ScvO2, central venous oxygen saturation.
Reproduced with permission from Kasnitz and coworkers [29].than PAC, but at the same time they have their own
limitations. In our view, the most relevant difference between
PAC and other haemodynamic monitoring is that the PAC – a
single device – permits assessment CO, several preload and
fluid challenge tolerances (CEDV and PAOP) and provides a
global index of whether oxygen transport is adequate for
demand (SvO2). Continuous measurement of all of this
information transforms the PAC into an integrated
physiological device.
Insertion of a PAC is rational if, and only if, all parameters are
considered as a whole. The issue is not whether the insertion
of a PAC per se will improve the prognosis of critically ill
patients or high-risk surgical patients, but whether PAC
parameters taken together as an integrated component of
treatment decision making can improve patient outcomes.
Indeed, no monitoring device, regardless of how accurate,
invasive, or sophisticated it is, will improve outcome if it is not
associated with a specific treatment, taking into account the
device’s specificity and with an appreciation of the underlying
physiopathology. No benefit in terms of outcome is
associated with the mere use of echocardiography, blood gas
sampling, or determination of blood lactate concentration, but
will we cease to use them? Of course not!
It is surprising that no controlled trial of a goal-directed
therapy using PAC is actually being conducted. We present
an example of an algorithm, adapted from that proposed by
Pinsky and Vincent [54] (Figure 4), which could be used in
the design of such a trial. Of course, this simple algorithm is
not universal and may require modification based on the
specificity and the severity of the pathology. Other
parameters from different monitoring devices (such as
variation in arterial pressure during mechanical ventilation to
Critical Care    Vol 10 Suppl 3 Robin et al.
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Figure 4
PAC-guided treatment protocol. Therapeutic options to be considered are given in rectangles. CCO, continuous cardiac output; CEDV, continuous
end-diastolic volume; O2ER, oxygen extraction ratio; PAOP, pulmonary artery occlusion pressure; PEEP, positive end-expiratory pressure; RVEF,
right ventricular ejection fraction; SaO2, arterial oxygen saturation; SvO2, mixed venous oxygen saturation; VO2, oxygen consumption. Reproduced
with permission from Pinsky and Vincent [54].assess preload  dependency) could be integrated into this
strategy. We now need a clinical trial using PAC parameters in
a treatment algorithm to determine whether PAC use can
improve outcomes in critically ill and high-risk surgical patients.
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